1-855-378-42281-855-378-4228
One of the outpatient rehabilitation alternatives for people in Bern who are battling with opioid dependence and addiction is opioid maintenance therapy. Some facilities and doctors are authorized to administer specific medications to opioid addicted individuals, many that are opioid-based themselves and are addiction. In low doses the individual does not experience high feelings but also doesn't experience acute cravings and is not experiencing opioid withdrawal. Methadone is the first medication used for this sole purpose, but there are a few more options currently to choose from.
Methadone is an opioid and is meant to be taken at an out-patient medical center licensed to administer the drug, which is taken on a daily basis in liquid or pill form. The cost of the drug is around under $200 per month. Buprenorphine is also an opiate based med, and is in pill form often taken one day on, one day off. But unlike Methadone which can only be given in highly well-regulated clinics, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The cost monthly of buprenorphine is about $300 /month for the generic version of the medication. There is also a type of buprenorphine that contains naloxone, which is a med that reverses the effects of opioids. A person taking this formulation, also known as Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It is also taken daily, and is priced about $450 monthly. Naltrexone is an additional med taken in opioid maintenance therapy, but unlike the other medications aforementioned it is an opiate blocker and isn't an opiate. A person has the choice to take this drug as a monthly injection, and that is called Vivitrol. As an opioid blocker, it prevents a person from experience high feelings from opioids, and therefore lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 a month.
For All Alcohol and Drug Treatment Programs In Bern, Click Here.
